Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc AGRX

Alternate Symbol(s):  AGXRW

Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a... see more

Recent & Breaking News (OTCPK:AGRX)

Agile Therapeutics Reports First Quarter 2020 Financial Results

GlobeNewswire May 5, 2020

Agile Therapeutics to Host First Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, May 5, 2020

GlobeNewswire April 23, 2020

Agile Therapeutics Announces Changes to its Board of Directors

GlobeNewswire April 22, 2020

Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020

GlobeNewswire February 25, 2020

Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

GlobeNewswire February 21, 2020

Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire February 20, 2020

Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 20, 2020

FDA Approves Agile Therapeutics, Inc.'s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System - A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

GlobeNewswire February 14, 2020

Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors

GlobeNewswire February 10, 2020

Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

GlobeNewswire January 6, 2020

Agile Therapeutics Strengthens Commercial Leadership Team

GlobeNewswire January 2, 2020

Agile Therapeutics to Present at Biotech Showcase(TM) 2020 in San Francisco

GlobeNewswire December 19, 2019

Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

GlobeNewswire November 14, 2019

Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

GlobeNewswire October 30, 2019

Agile Therapeutics Reports Third Quarter 2019 Financial Results

GlobeNewswire October 28, 2019

Agile Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 6, 2019

Agile Therapeutics Announces Full Exercise of Over-Allotment Option by Underwriters

GlobeNewswire August 8, 2019

Agile Therapeutics Announces Pricing of $12 Million Underwritten Public Offering of Common Stock

GlobeNewswire August 2, 2019

Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire August 1, 2019

Agile Therapeutics Reports Second Quarter 2019 Financial Results

GlobeNewswire August 1, 2019